| Host: |
E. coli |
| Reactivity: |
SARS-CoV-2 |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-SARS-COV-2 Nucleocapsid (B.1.1.529/Omicron)-C-His protein was developed from e. coli and has a target region of C-His. For use in research applications. |
| Formulation: |
Supplied as a 0.22 Mu m filtered solution in 20mM TRIS, 500mM NaCl, 0.1mM EDTA, 10% Glycerol, pH8.0. |
| Immunoreactivity: |
Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2 Envelope at 2 Mu g/mL (100 Mu L/well) can bind SARS-COV-2 Nucleocapsid with a linear range of 0.2-65 ng/mL. |
| Immunogen: |
Recombinant SARS-COV-2 Nucleocapsid (B.1.1.529/Omicron) Protein is produced by E. coli expression system. The target protein is expressed with sequence (Ser2-Ala419 (P13L, E31del, R32del, S33del, R203K, G204R) ) of sars-cov-2 N (B.1.1.529/Omicron) (A |
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
